ABSTRACT
Background On March 15, 2020 Puerto Rico implemented non-pharmaceutical interventions (NPIs), including a mandatory curfew, as part of a state of emergency declaration to mitigate the community transmission of the SARS-CoV-2 virus. The strict enforcement of this curfew was extended through May 25, with a gradual relaxation beginning on May 1. This report summarizes an assessment of these early mitigation measures on the progression of COVID-19 in the island.
Methods and Findings From March 15 to May 15, 2020, 41,748 results of molecular (RT-PCR) tests were reported to the Puerto Rico Department of Health. Of these, 1,866 (4.5%) were positive, corresponding to 1,219 individuals with COVID-19 included in the study. We derived the epidemic growth rates (r) and the corresponding reproductive numbers (R) from the epidemic curve of these 1,219 individuals with laboratory-confirmed diagnosis of COVID-19 using their date of test collection as a proxy for symptoms onset. We then compared the observed cases with the R-based epidemic model projections had the mitigation measures not been implemented. Computations were conducted in the R packages forecast, incidence and projections.
The number of daily RT-PCR-confirmed cases peaked on March 30 (84 cases), showing a weekly cyclical trend, with lower counts on weekends and a decreasing secular trend since March 30. The initial exponential growth rate (r) was 17.0% (95% CI: 8.4%, 25.6%), corresponding to a doubling of cases every 4.1 days, and to a reproduction number (Ro) of 1.89 (95% CI: 1.41, 2.39). After March 30, the r value reverted to an exponential decay rate (negative) of −3.6% (95% CI: −5.7%, −1.4%), corresponding to a halving of cases every 19.4 days and to an Ro of 0.90 (95% CI: 0.84, 0.97). Had the initial growth rate been maintained, a total of 18,699 (96%CI: 4,113, 87,438) COVID-19 cases would have occurred by April 30 compared with 1,119 observed.
Conclusions Our findings are consistent with very effective implementation of early non-pharmaceutical interventions (NPIs) as mitigation measures in Puerto Rico. These results serve as a baseline to assess the impact of the transition from mitigation to containment stages in Puerto Rico.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Category of exemption: D. Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. https://irbrcm.rcm.upr.edu/wp-content/uploads/sites/21/2020/04/Procedure-for-Determining-Exemptions.pdf
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The public data used for our study was anonymized prior to our team having access. The Puerto Rico Department of Health anonymized the data. The public data is available at the URL below. The specific subset of the pubic data set used for our analysis (including the R code) will be made available upon acceptance of manuscript by PLOS Medicine.
